Share

November 2016Research

Guillain-Barré syndrome after surgical procedures

Predisposing factors and outcome

Elanagan Nagarajan, Mark Rubin, Eelco F.M. Wijdicks, Sara E. Hocker
First published November 23, 2016, DOI: https://doi.org/10.1212/CPJ.0000000000000329
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
897

Share

This article has corrections. Please see:

Article Information

10.1212/CPJ.0000000000000329
DOI: 
https://doi.org/10.1212/CPJ.0000000000000329
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received June 3, 2016
  • Accepted August 11, 2016
  • First Published November 23, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology

Author Disclosures

    1. Elanagan Nagarajan, MD,
    2. Mark Rubin, MD,
    3. Eelco F.M. Wijdicks, MD and
    4. Sara E. Hocker, MD
  1. Elanagan Nagarajan, MD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Mark Rubin, MD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Eelco F.M. Wijdicks, MD and
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editor-in-Chief, Neurocritical Care, 2004-2012

    Patents:

    1. NONE

    Publishing Royalties:

    1. Books published by Oxford University Press

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Sara E. Hocker, MD
    5. Scientific Advisory Boards:

    1. I perform consulting activities for SAGE therapeutics for a phase 3 clinical trial of allopregnanolone for which I receive financial compensation.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. I receive speaker honoraria from the AAN and honoraria from Continuum.

    Editorial Boards:

    1. 07/2015 ? present. Frontiers in Neurology Education (Associate Editor)01/2015 ? present. Journal of Stroke and Cerebrovascular Diseases (Editorial Board member)03/2012 ? present. Frontiers in Stroke (Review Editor)04/2011 ? present. Frontiers in Neurocritical and Neurohospitalist Care (Review Editor)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Department of Neurology (EN, EFMW, SEH), Mayo Clinic, Rochester, MN; Department of Neurology (MR), Northshore University Health System, Glenview, IL; and Department of Neurology, Mayo Clinic, Scottsdale, AZ.
  1. Correspondence to:
    hocker.sara{at}mayo.edu

Article usage

Article usage: November 2016 to October 2023

AbstractFullPdfSource
Nov 20169472125Highwire
Dec 20161137042Highwire
Jan 201743807Highwire
Feb 201729305Highwire
Mar 201716606Highwire
Apr 201715601Highwire
May 201712000Highwire
Jun 20177607Highwire
Jul 201712003Highwire
Aug 201710703Highwire
Sep 20178200Highwire
Oct 201713202Highwire
Nov 201717404Highwire
Dec 2017491024Highwire
Jan 2018382030Highwire
Feb 2018341030Highwire
Mar 2018248031Highwire
Apr 2018325028Highwire
May 2018330030Highwire
Jun 2018207027Highwire
Jul 2018153030Highwire
Aug 2018199030Highwire
Sep 2018224030Highwire
Oct 2018155029Highwire
Nov 2018160029Highwire
Dec 2018146012Highwire
Jan 2019138017Highwire
Feb 2019108026Highwire
Mar 2019127020Highwire
Apr 2019131015Highwire
May 2019100017Highwire
Jun 20198209Highwire
Jul 201996016Highwire
Aug 201911009Highwire
Sep 20196203Highwire
Oct 2019138019Highwire
Nov 2019175012Highwire
Dec 201914009Highwire
Jan 2020136011Highwire
Feb 2020134014Highwire
Mar 202015509Highwire
Apr 202013709Highwire
May 202010303Highwire
Jun 20209909Highwire
Jul 20208806Highwire
Aug 202010905Highwire
Sep 202012006Highwire
Oct 202010702Highwire
Nov 202011807Highwire
Dec 202010103Highwire
Jan 20218801Highwire
Feb 202110401Highwire
Mar 202110501Highwire
Apr 20218600Highwire
May 20217805Highwire
Jun 202116205Highwire
Jul 202111402Highwire
Aug 202110005Highwire
Sep 202110504Highwire
Oct 202110805Highwire
Nov 20216604Highwire
Dec 202110009Highwire
Jan 202211706Highwire
Feb 20228705Highwire
Mar 20229709Highwire
Apr 202211001Highwire
May 202213802Highwire
Jun 202213502Highwire
Jul 202221000Highwire
Aug 202227500Highwire
Sep 202225903Highwire
Oct 202213701Highwire
Nov 202218100Highwire
Dec 202212701Highwire
Jan 202310500Highwire
Feb 202314400Highwire
Mar 202314402Highwire
Apr 202311000Highwire
May 202315900Highwire
Jun 202310501Highwire
Jul 202320600Highwire
Aug 20237700Highwire
Sep 20237801Highwire
Oct 202312700Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me